Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:PTN)

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

PR Newswire 1 day ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

PR Newswire 12 days ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

PR Newswire November 8, 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

PR Newswire November 4, 2024

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

PR Newswire October 31, 2024

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

PR Newswire October 24, 2024

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

PR Newswire October 23, 2024

Palatin Receives Notice of Non-Compliance from NYSE American

PR Newswire October 7, 2024

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

PR Newswire October 1, 2024
View More News ››

Opinion & Analysis (NYSEAM:PTN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:PTN)

Palatin Reports First Quarter Fiscal Year 2025 Operating/Fin

News; $PTN Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial ResultsPalatin Reports First Quarter Fiscal Year 2025...
whytestocks - 12 days ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Te

Breaking News: $PTN Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14...
whytestocks - November 8, 2024

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Fi

News; $PTN Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic...
whytestocks - October 1, 2024

First Patient Dosed in Phase 2 Clinical Study of Palatin's B

NEWS: $PTN First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the...
whytestocks - August 22, 2024

Palatin Announces Exercise of Warrants for Approximately $6.

Just In: $PTN Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross ProceedsPalatin Announces Exercise of Warrants...
whytestocks - June 21, 2024

Palatin Initiates Phase 2 Clinical Study of Bremelanotide fo

JUST IN: $PTN Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityPalatin Initiates Phase 2 Clinical...
whytestocks - June 12, 2024
View more Bullboard ››

Nextleaf Solutions Ltd

Nextleaf Solutions Ltd

Nextleaf Solutions Ltd. is a cannabis processor with a portfolio of federally regulated emerging consumer brands, market ...
View More »